Financials
Financial year 2025
Danis Pharma from Beersel, company number BE0465345721, closed financial year 2025 with a result of € 71,707 after tax. For that financial year Danis Pharma recorded a gross margin of € 113,647 and equity of € 784,088. Compared with financial year 2024, the result moved from € 82,319 to € 71,707. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 29, 2026.
€ 784,088
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 71,707
▼ 13% vs 2024
Profit after tax over the fiscal year.
€ 69,907
▼ 51% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 722,115.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 37,175
▼ 25% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 158,993 | € 118,241 | € 124,638 | € 113,647 | ▼ 9% |
| Profit after taxes | € 100,954 | € 73,067 | € 82,319 | € 71,707 | ▼ 13% |
| Equity | € 556,995 | € 630,062 | € 712,381 | € 784,088 | ▲ 10% |
| Total debts | € 212,997 | € 112,750 | € 107,096 | € 82,012 | ▼ 23% |
| Cash | € 405,980 | € 141,703 | € 143,690 | € 69,907 | ▼ 51% |
| Land & buildings | € 91,102 | € 110,845 | € 103,436 | € 104,974 | ▲ 1% |
| Retained profit | € 495,021 | € 568,089 | € 650,408 | € 722,115 | ▲ 11% |
| Bank debt | € 69,330 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 769,992 | € 742,812 | € 819,478 | € 866,100 | ▲ 6% |
Key figures of Danis Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to Danis Pharma?
What happened at Danis Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 71,707 (▼ 13% vs 2024). Source: NBB ↗
- New establishment in Beersel. KBO
- Start of the company according to the CBE. KBO
In short
From € 100,954 profit in 2022 to € 71,707 profit in 2025.
Paid € 115,171 in corporate taxes since 2022.
Best year ever: 2022, with € 100,954 profit.
Management
The stake of Maasdender comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Danis PharmaBehind Danis Pharma are Philippe Vanneste and Danuta Osiadacz. The shares are held by Maasdender (98.8%).
Directors
According to the 2025 annual accounts
Shareholders
98.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Danislaan 13
1650 Beersel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
one.com Mail
Hosting
ONECOM, DK
Website info
Features
Security
Network
Details
- Company number
- 0465.345.721
- VAT number
- BE 0465.345.721
- Registered office
- Danislaan 13, 1650 Beersel
- Names & denominations
- Danis Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 January 1999
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- danispharma.be
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers